Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma
Stem Cell Investigation · 2016-10-31 · 3 · 70-70
DOI: 10.21037/sci.2016.09.13 ↗At a glance
Übersichtsarbeit in Stem Cell Investigation, published online on 2016-10-31. Written by Shigeo Fuji and 1 co-authors. Institution: Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan. Cited 43 times so far (Crossref). The full text is freely available in PubMed Central.
Abstract (original language)
Intet abstract tilgængeligt.
Subjects
Author keywords
Authors and institutions
- Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
- Department of Hematology, Respiratory Medicine and Oncology, Saga University School of Medicine, Saga, Japan.
Cite
APA
Fuji, S., & Shindo, T. (2016). Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. Stem Cell Investigation, 3, 70-70. https://doi.org/10.21037/sci.2016.09.13
Vancouver
Fuji S, Shindo T. Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. Stem Cell Investigation. 2016;3:70-70. doi:10.21037/sci.2016.09.13
BibTeX
@article{Fuji2016,
author = {Fuji, Shigeo and Shindo, Takero},
title = {Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma},
journal = {Stem Cell Investigation},
year = {2016},
volume = {3},
pages = {70--70},
doi = {10.21037/sci.2016.09.13}
}
EUVIMED